Erratum to Treatment strategies for patients with HER2-positive gastric cancer
2024-05-18 10:21:56FeixueWangYiBa
Cancer Biology & Medicine
2024年3期
Feixue Wang, Yi Ba,2
1Department of GI Medical Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin’s Clinical Research Center for Cancer, Tianjin Key Laboratory of Digestive Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University, Tianjin 300060, China; 2Department of Medical Oncology, Department of Cancer Center, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing 100032, China
For the affiliation information, the affiliation for author Feixue Wang should be Department of GI Medical Oncology,Tianjin Medical University Cancer Institute and Hospital,National Clinical Research Center for Cancer, Tianjin’s Clinical Research Center for Cancer, Tianjin Key Laboratory of Digestive Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University, Tianjin 300060,China.
登錄APP查看全文
Cancer Biology & Medicine
2024年3期
- Cancer Biology & Medicine的其它文章
- DNA damage response-related immune activation signature predicts the response to immune checkpoint inhibitors: from gastrointestinal cancer analysis to pan-cancer validation
- Bronchoalveolar lavage fluid assessment facilitates precision medicine for lung cancer
- A retrospective analysis of mature T- and NK-cell lymphomas
- Current status of early gastric cancer screening research
- Cervical cancer prevention in China: where are we now,and what’s next?
- Reducing the global cancer burden with gastrointestinal screening: China’s 30 years practice